Navigation Links
Psylin Neurosciences Commences Development of Compound for Depression
Date:4/20/2009

in vivo approach to drug discovery," said Emer Leahy, Ph.D., Co-CEO of Psylin and President and CEO of PsychoGenics. "PSN0041 is a very exciting molecule that offers a new approach to the treatment of depression and based on our preclinical models is expected to provide certain unique advantages over existing treatments."

Psylin's mission is to pioneer the development of peptide therapeutics for the treatment of psychiatric disorders. PSN0041 will be the first compound in Psylin's pipeline to enter into clinical development. Other compounds are being investigated for development as antipsychotic and mood stabilizing therapies.

Amylin's proprietary peptide library known as PHORMOL encompasses an extensive panel of potentially valuable biologics that have been taken from nature, including human peptides not previously described. All of these have been synthesized to create a rich source of compounds that are being evaluated for potential utility in a range of diseases.

PsychoGenics' proprietary drug discovery technologies combine its broad in vivo behavioral expertise with recent developments in robotics, computer vision and bio/cheminformatics to evaluate drug candidates for potential utility across the spectrum of neuropsychiatric disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for a variety of early and late stage compounds including some with novel "first-in-class" mechanisms of action such as PSN0041.

About Depression

Depression is the leading major cause of disability in the United States. According to the National Institute of Mental Health, depression affects approximately 19 million people in the United States. The U.S. Surgeon General estimates that the indirect costs attributable to depression amount to $80 billion annually.


'/>"/>

SOURCE Psylin Neurosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
2. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
3. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
4. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
5. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
6. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
7. Amarin Signs Agreement to Acquire Ester Neurosciences
8. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Results from a Phase III clinical trial examining ... reduce the size of melanoma tumors in patients injected ... of Clinical Oncology. , The global, randomized trial ... melanoma, a potentially fatal form of skin cancer. The ... safety and efficacy of the oncolytic virus immunotherapy compared ...
(Date:5/28/2015)... MADISON, N.J. , May 28, 2015  Quest ... provider of diagnostic information services, announced that it is ... Conference in New York.  Steve Rusckowski , the ... goals and five point strategy.  The presentation is scheduled ... Time. The presentation will be webcast live ...
(Date:5/28/2015)... DUBLIN , May 27, 2015 ... addition of Jain PharmaBiotech,s new report "Neuroprotection ... offering. This report describes the role ... and injuries of the nervous system as well ... because many of the underlying mechanisms of damage ...
(Date:5/28/2015)... BioNorth Texas (BioNorthTX), an independent, non-profit ... sciences industry in northern region of Texas, held ... Foundry in Dallas on April 27, 2015. The ... broad spectrum of biotech professionals from the North ... in partnering with key life sciences organizations both ...
Breaking Biology Technology:Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3
... - The next generation of high-performance wireless communication ... at the University of Wisconsin-Madison . , ,But ... the country, pursuing a technology 14 years in the ... diamond and the tiny electromechanical systems into ...
... - Recently, as I sat at lunch sending off ... but reflect on how our professional lives continue to evolve ... ,As the CEO of a company that is driving the ... impressed with how quickly technological change continues to transform and ...
... high-tech startup and spin-off companies are gaining attention ... example of this is Primorigen Biosciences LLC ... for analysis of cellular reprogramming and differentiation. , ... and related products, will use a pair of ...
Cached Biology Technology:Nano-diamond film studied at UW could advance telecommunications 2Nano-diamond film studied at UW could advance telecommunications 3Visions: Rimas Buinevicius, CEO of Sonic Foundry 2Visions: Rimas Buinevicius, CEO of Sonic Foundry 3Wisconsin start up Primorigen Biosciences corrals out-of-state investment 2
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... the second consecutive year, members of Virginia Tech,s ... in mechanical engineering, directed by professor Pavlos ... the Outstanding Paper Award in fluid mechanics from ... published by the American Institute of Physics. ...
... and Scott Ollinger of the University of New Hampshire,s ... (EOS) have received funding from the National Science Foundation ... for the agency,s new Macrosystems Biology program. The grant ... or so-called carbon "sources" and "sinks" in the long-term ...
... flat Prairie, you,d think a city would provide a good ... in trees and buildings. But researchers at the University of ... far from ideal for these animals. "I was really ... PhD graduate in biological sciences at the University of Calgary ...
Cached Biology News:Virginia Tech mechanical engineers win measurement science best paper award 2UNH researchers receive grant for pioneering carbon cycle model 2UNH researchers receive grant for pioneering carbon cycle model 3Big city holds empty promise for bats 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... of X-ray crystallography services for structure-based ... to its pharmaceutical and biotechnology clients. ... drug-like fragments to the active sites ... scientists to develop novel, high-affinity inhibitors. ...
...
... (AChE) activity. This is a highly sensitive, ... and easy to use assay for AChE ... A series of coupled enzyme reactions translates ... change in luminescence. Inhibitors of AChE are ...
Biology Products: